Free shipping on all orders over $ 500

MBX-2982

Cat. No. M3632

All AbMole products are for research use only, cannot be used for human consumption.

MBX-2982 Structure
Synonym:

MBX2982

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 75 In stock
1mg USD 30 In stock
5mg USD 68 In stock
10mg USD 95 In stock
25mg USD 220 In stock
50mg USD 330 In stock
100mg USD 480 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

MBX-2982 is a potent selective orally-active GPR119 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX-2982 stimulates release of the incretin GLP-1 from the gut. Treatment with MBX-2982 increased insulin, active GLP-1, and total GLP-1 during an extended MMTT. Treatment with MBX-2982 also tended to increase fasting insulin and c-peptide, and decrease fasting triglycerides. MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

Customer Product Validations & Biological Datas
Source Eur J Pharmacol (2015). Figure 5. MBX-2982
Method Examining the longevity of wash-resistant cAMP responses to GPR119 agonists
Cell Lines HEK-GPR119 cells.
Concentrations 30 nM
Incubation Time 60 min
Results These data are consistent with a requirement for membrane deposition in the sustained wash-resistant effects for MBX-2982 and AZ1, but not AR-231, 453.
Chemical Information
Molecular Weight 448.54
Formula C22H24N8OS
CAS Number 1037792-44-1
Solubility (25°C) DMSO ≥ 10 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Gater D. IDrugs. 32nd National Medicinal Chemistry Symposium--medicinal chemistry developments for neurodegeneration, diabetes and cancer.

[2] Jones RM, et al. Expert Opin Ther Pat. GPR119 agonists for the treatment of type 2 diabetes.

Related GPR/FFAR Products
GW9508

GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 has anti-inflammatory and anti-atherosclerotic activities. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener.

Fasiglifam (TAK-875) Hemihydrate

Fasiglifam (TAK-875) Hemihydrate is a novel, orally available, selective GPR40 agonist.

OC000459

OC000459 is a potent, selective, and orally active D prostanoid receptor 2 antagonist.

AMG-837

AMG 837 is a potent, orally bioavailable GPR40 agonist with EC50 of 14 nM.

AZD1981

AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1.

  Catalog
Abmole Inhibitor Catalog




Keywords: MBX-2982, MBX2982 supplier, GPR/FFAR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.